Sleep and Brain Health; Early Amyloid Vaccine Data; New ALS Trial Survival Analysis

About 7 hours a night was identified as the optimal sleep duration, using genetic and cognitive factors, brain structure, and mental health as key measures, U.K. Biobank data showed. (Nature Aging)

Medicare policy changes were associated with a drop in hospice use among people with Alzheimer’s and dementia. (JAMA Health Forum)

The ACI-24 anti-amyloid vaccine was safe and elicited immunogenicity in 4 of 12 participants in a phase Ib trial of adults with Down syndrome. (JAMA Neurology)

Of 16,225 patients with severe SARS-CoV-2, 12.9% developed serious neurologic manifestations, mainly encephalopathy. (Critical Care Explorations)

Cognitive impairment from severe COVID-19 was equivalent to about 20 years of aging, a small study suggested. (eClinicalMedicine)

A new analysis of phase II trial data that accounted for placebo crossover showed a 10.6-month longer median survival duration among amyotrophic lateral sclerosis (ALS) patients who received investigational sodium phenylbutyrate and taurursodiol (AMX0035). The FDA is expected to decide whether to approve AMX0035 by June 29. (Muscle & Nerve)

Pfizer will acquire Biohaven Pharmaceuticals, maker of rimegepant (Nurtec), an oral tablet approved to treat acute migraine and prevent episodic migraine.

Biogen and MedRhythms will develop an investigational digital therapy to help multiple sclerosis patients improve their gait using music, software, and sensors.

Of 10 transcriptionally defined populations of dopamine neurons in the substantia nigra, only one was highly susceptible to neurodegeneration in Parkinson’s disease. (Nature Neuroscience)

Reframing post-concussion syndrome as an interface disorder of neurology, psychiatry, and psychology may help improve treatment, researchers suggested. (Brain)

Which came first, the carb cravings or the migraine? (New York Times)